Unraveling the Molecular Mechanisms Involved in HCV-Induced Carcinogenesis

Viruses. 2022 Dec 11;14(12):2762. doi: 10.3390/v14122762.

Abstract

Cancer induced by a viral infection is among the leading causes of cancer. Hepatitis C Virus (HCV) is a hepatotropic oncogenic positive-sense RNA virus that leads to chronic infection, exposing the liver to a continuous process of damage and regeneration and promoting hepatocarcinogenesis. The virus promotes the development of carcinogenesis through indirect and direct molecular mechanisms such as chronic inflammation, oxidative stress, steatosis, genetic alterations, epithelial-mesenchymal transition, proliferation, and apoptosis, among others. Recently, direct-acting antivirals (DAAs) showed sustained virologic response in 95% of cases. Nevertheless, patients treated with DAAs have reported an unexpected increase in the early incidence of Hepatocellular carcinoma (HCC). Studies suggest that HCV induces epigenetic regulation through non-coding RNAs, DNA methylation, and chromatin remodeling, which modify gene expressions and induce genomic instability related to HCC development that persists with the infection's clearance. The need for a better understanding of the molecular mechanisms associated with the development of carcinogenesis is evident. The aim of this review was to unravel the molecular pathways involved in the development of carcinogenesis before, during, and after the viral infection's resolution, and how these pathways were regulated by the virus, to find control points that can be used as potential therapeutic targets.

Keywords: carcinogenesis; epithelial-mesenchymal transition; hepatitis C virus; hepatocellular carcinoma; inflammation; proliferation.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / pharmacology
  • Carcinogenesis / genetics
  • Carcinoma, Hepatocellular* / genetics
  • Epigenesis, Genetic
  • Hepacivirus / genetics
  • Hepatitis C* / drug therapy
  • Hepatitis C, Chronic* / drug therapy
  • Humans
  • Liver Neoplasms* / genetics

Substances

  • Antiviral Agents

Grants and funding

The APC was funded by the Department of Biochemistry and Molecular Medicine and CIIViM, School of Medicine, and by PAICYT 171-CS-2022 from Universidad Autónoma de Nuevo León (UANL), Monterrey, Nuevo León 64460, Mexico.